Pregnancy Clinical Trial
— AMIGOSOfficial title:
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.
Status | Completed |
Enrollment | 900 |
Est. completion date | March 2014 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Women =18 to =40 years of age, with one or more years infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation. 2. Normal uterine cavity and at least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography, or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the subject did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion. 3. Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH =12 IU/L within one year prior to study initiation. 4. Normal or corrected thyroid function within one year of study initiation. 5. Normal prolactin level within one year of study initiation. 6. In general good health, not taking any medications which could interfere with the study (e.g., FSH, insulin sensitizers). 7. Ability to have inseminations following hCG administration. 8. Male partner with total motile sperm in the ejaculate of at least 5 million sperm, within one year of study initiation. Exclusion Criteria: 1. Currently pregnant or successful pregnancies within 12 months of initiating participation. Clinical intrauterine miscarriages prior to initiating participation, within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35 must wait 12 months. No exclusion for biochemical pregnancies. 2. Undiagnosed abnormal uterine bleeding. 3. Suspicious ovarian mass. 4. Patients on oral contraceptives, depo-progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially when the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins. 5. Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal hyperplasia. 6. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications. 7. Known significant anemia (Hemoglobin <10 g/dL). 8. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event. 9. Known heart disease (New York Heart Association Class II or higher). 10. Known Liver disease (defined as AST or ALT>2 times normal, or total bilirubin >2.5 mg/dL). 11. Known Renal disease (defined as BUN >30 mg/dL or serum creatinine > 1.4 mg/dL). 12. History of, or suspected cervical carcinoma, endometrial carcinoma or breast carcinoma. 13. History of alcohol abuse (defined as >14 drinks/week) or binge drinking of = 6 drinks at one time). 14. Known Cushing's disease. 15. Known or suspected adrenal or ovarian androgen secreting tumors. 16. Allergy or contraindication to the treatment medications: AI, gonadotropins, CC or hCG. 17. Couples with previous sterilization procedures (e.g. vasectomy, tubal ligation) which have been reversed. 18. Patients with untreated poorly controlled hypertension defined as a systolic blood pressure = 160 mm Hg or a diastolic = 100 mm Hg obtained on two measures obtained at least 60 minutes apart. 19. Subjects who have undergone a bariatric surgery procedure in the recent past (< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon. 20. Known moderate or severe endometriosis 21. Known polycystic ovarian syndrome as evidenced by anovulation or oligoovulation, hirsutism and/or elevated testosterone levels, and ovarian morphology on ultrasound examination. 22. Donated semen. 23. Couples in which either partner is legally married to someone else. 24. Medical conditions that are contraindications to pregnancy. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Colorado | Aurora | Colorado |
United States | University of Alabama Birmingham | Birmingham | Alabama |
United States | University of Vermont | Burlington | Vermont |
United States | Carolinas Medical Center | Charlotte | North Carolina |
United States | Wayne State University | Detroit | Michigan |
United States | Pennsylvania State University College of Medicine | Hershey | Pennsylvania |
United States | Yale University | New Haven | Connecticut |
United States | University of Medicine and Dentistry of New Jersey | Newark | New Jersey |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
United States | University of California, San Francisco | San Francisco | California |
United States | Stanford University Medical Center | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Yale University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Penn State University, University of Colorado, Denver, University of Michigan, University of Pennsylvania, University of Texas, University of Vermont, Wayne State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. | Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks | Yes | |
Secondary | Rate of Pregnancy Obtained | Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks | No | |
Secondary | Time to Pregnancy | Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks | No | |
Secondary | Live Birth Rate | Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |